Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 149

1.

Loss of Interleukin 1 Receptor Antagonist Enhances Susceptibility to Ebola Virus Infection.

Hill-Batorski L, Halfmann P, Marzi A, Lopes TJ, Neumann G, Feldmann H, Kawaoka Y.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S329-35. doi: 10.1093/infdis/jiv335. Epub 2015 Jul 23.

2.

Development of a murine model for aerosolized ebolavirus infection using a panel of recombinant inbred mice.

Zumbrun EE, Abdeltawab NF, Bloomfield HA, Chance TB, Nichols DK, Harrison PE, Kotb M, Nalca A.

Viruses. 2012 Dec 3;4(12):3468-93. doi: 10.3390/v4123468. Review.

3.

Functional CD8+ T cell responses in lethal Ebola virus infection.

Bradfute SB, Warfield KL, Bavari S.

J Immunol. 2008 Mar 15;180(6):4058-66.

4.

VSVΔG/EBOV GP-induced innate protection enhances natural killer cell activity to increase survival in a lethal mouse adapted Ebola virus infection.

Williams KJ, Qiu X, Fernando L, Jones SM, Alimonti JB.

Viral Immunol. 2015 Feb;28(1):51-61. doi: 10.1089/vim.2014.0069.

PMID:
25494457
5.
6.

Ebolaviruses Associated with Differential Pathogenicity Induce Distinct Host Responses in Human Macrophages.

Olejnik J, Forero A, Deflubé LR, Hume AJ, Manhart WA, Nishida A, Marzi A, Katze MG, Ebihara H, Rasmussen AL, Mühlberger E.

J Virol. 2017 May 12;91(11). pii: e00179-17. doi: 10.1128/JVI.00179-17. Print 2017 Jun 1.

7.

Interferon α/β Receptor-Deficient Mice as a Model for Ebola Virus Disease.

Brannan JM, Froude JW, Prugar LI, Bakken RR, Zak SE, Daye SP, Wilhelmsen CE, Dye JM.

J Infect Dis. 2015 Oct 1;212 Suppl 2:S282-94. doi: 10.1093/infdis/jiv215. Epub 2015 May 4.

PMID:
25943199
8.

Early immune responses accompanying human asymptomatic Ebola infections.

Leroy EM, Baize S, Debre P, Lansoud-Soukate J, Mavoungou E.

Clin Exp Immunol. 2001 Jun;124(3):453-60.

9.

Development of a cAdVax-based bivalent ebola virus vaccine that induces immune responses against both the Sudan and Zaire species of Ebola virus.

Wang D, Raja NU, Trubey CM, Juompan LY, Luo M, Woraratanadharm J, Deitz SB, Yu H, Swain BM, Moore KM, Pratt WD, Hart MK, Dong JY.

J Virol. 2006 Mar;80(6):2738-46.

10.

Human fatal zaire ebola virus infection is associated with an aberrant innate immunity and with massive lymphocyte apoptosis.

Wauquier N, Becquart P, Padilla C, Baize S, Leroy EM.

PLoS Negl Trop Dis. 2010 Oct 5;4(10). pii: e837. doi: 10.1371/journal.pntd.0000837.

11.

Lipopolysaccharide of Aggregatibacter actinomycetemcomitans up-regulates inflammatory cytokines, prostaglandin E2 synthesis and osteoclast formation in interleukin-1 receptor antagonist-deficient mice.

Mizutani H, Ishihara Y, Izawa A, Fujihara Y, Kobayashi S, Gotou H, Okabe E, Takeda H, Ozawa Y, Kamiya Y, Kamei H, Kikuchi T, Yamamoto G, Mitani A, Nishihara T, Noguchi T.

J Periodontal Res. 2013 Dec;48(6):748-56. doi: 10.1111/jre.12065. Epub 2013 Apr 16.

PMID:
23586622
12.

Specific neutralizing response in plasma from convalescent patients of Ebola Virus Disease against the West Africa Makona variant of Ebola virus.

Luczkowiak J, Arribas JR, Gómez S, Jiménez-Yuste V, de la Calle F, Viejo A, Delgado R.

Virus Res. 2016 Feb 2;213:224-229. doi: 10.1016/j.virusres.2015.12.019. Epub 2015 Dec 29.

PMID:
26739425
13.

Delayed resolution of lung inflammation in Il-1rn-/- mice reflects elevated IL-17A/granulocyte colony-stimulating factor expression.

Hudock KM, Liu Y, Mei J, Marino RC, Hale JE, Dai N, Worthen GS.

Am J Respir Cell Mol Biol. 2012 Oct;47(4):436-44. doi: 10.1165/rcmb.2012-0104OC. Epub 2012 May 16.

14.

Ebola Virus Binding to Tim-1 on T Lymphocytes Induces a Cytokine Storm.

Younan P, Iampietro M, Nishida A, Ramanathan P, Santos RI, Dutta M, Lubaki NM, Koup RA, Katze MG, Bukreyev A.

MBio. 2017 Sep 26;8(5). pii: e00845-17. doi: 10.1128/mBio.00845-17.

15.

The VP35 protein of Ebola virus impairs dendritic cell maturation induced by virus and lipopolysaccharide.

Jin H, Yan Z, Prabhakar BS, Feng Z, Ma Y, Verpooten D, Ganesh B, He B.

J Gen Virol. 2010 Feb;91(Pt 2):352-61. doi: 10.1099/vir.0.017343-0. Epub 2009 Oct 14.

16.

Induction of humoral and CD8+ T cell responses are required for protection against lethal Ebola virus infection.

Warfield KL, Olinger G, Deal EM, Swenson DL, Bailey M, Negley DL, Hart MK, Bavari S.

J Immunol. 2005 Jul 15;175(2):1184-91.

17.

Suppressor of Cytokine Signaling 3 Is an Inducible Host Factor That Regulates Virus Egress during Ebola Virus Infection.

Okumura A, Rasmussen AL, Halfmann P, Feldmann F, Yoshimura A, Feldmann H, Kawaoka Y, Harty RN, Katze MG.

J Virol. 2015 Oct;89(20):10399-406. doi: 10.1128/JVI.01736-15. Epub 2015 Aug 5.

18.

Inflammatory bone loss in experimental periodontitis induced by Aggregatibacter actinomycetemcomitans in interleukin-1 receptor antagonist knockout mice.

Izawa A, Ishihara Y, Mizutani H, Kobayashi S, Goto H, Okabe E, Takeda H, Ozawa Y, Kamiya Y, Sugita Y, Kubo K, Kamei H, Kikuchi T, Mitani A, Hayashi J, Nishihara T, Maeda H, Noguchi T.

Infect Immun. 2014 May;82(5):1904-13. doi: 10.1128/IAI.01618-13. Epub 2014 Feb 24.

19.

Humanized Mouse Model of Ebola Virus Disease Mimics the Immune Responses in Human Disease.

Bird BH, Spengler JR, Chakrabarti AK, Khristova ML, Sealy TK, Coleman-McCray JD, Martin BE, Dodd KA, Goldsmith CS, Sanders J, Zaki SR, Nichol ST, Spiropoulou CF.

J Infect Dis. 2016 Mar 1;213(5):703-11. doi: 10.1093/infdis/jiv538. Epub 2015 Nov 17.

20.

Sustained protection against Ebola virus infection following treatment of infected nonhuman primates with ZMAb.

Qiu X, Audet J, Wong G, Fernando L, Bello A, Pillet S, Alimonti JB, Kobinger GP.

Sci Rep. 2013 Nov 28;3:3365. doi: 10.1038/srep03365.

Supplemental Content

Support Center